Xcout Intel
ABIONYX PHARMA
ABIONYX Pharma is a biotech company that develops innovative therapies for severe diseases and rare conditions with no effective existing treatments. The company focuses on creating drugs for renal and ophthalmological diseases, as well as new HDL vectors for targeted drug delivery and treatments for severe inflammation and sepsis.
Subscribe to see ABIONYX PHARMA’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ABIONYX PHARMA at a glance
ABIONYX PHARMA is a biotech company headquartered in France. Xcout tracks 9 named people at ABIONYX PHARMA, including Cyrille Tupin (CEO).
ABIONYX PHARMA leadership
- Cyrille TupinCEO
- Emmanuel HuynhChairman
- Laura A. CoruzziSenior Vice President, Intellectual Property REGENXBIO Inc.
- Christian ChavyChief Executive Officer of Stallergenes
- Caroline DeSurmontDirector
- Jean-Gérard GalvezDirector
3 more named people on record for ABIONYX PHARMA, with roles, board committees and tenure — see the full roster →
ABIONYX PHARMA competitors
A few of ABIONYX PHARMA's closest competitors — see the full list of competitors and alternatives →
Rallybio is a clinical-stage biotechnology company that develops therapies for patients with severe and rare diseases, focusing on areas such as complement dysregulation and hematology. The company's pipeline includes therapeutic assets like C5 inhibitors designed to address significant unmet medical needs.
Aurion Biotech Inc. develops regenerative cell therapies for ophthalmology, focusing on treatments for corneal endothelial disease and vision loss. Its lead product, AURN001, is a combination therapy utilizing human corneal endothelial cells designed to restore corneal clarity and provide a minimally invasive alternative to traditional donor tissue transplantation. The company serves patients suffering from blindness and provides advanced treatment options for ophthalmologists.
Healx is an AI-native pharmaceutical company that uses artificial intelligence and technology to discover and develop new treatments for rare diseases. The company redevelops, combines, and enhances known compounds to build a drug pipeline aimed at delivering effective therapies to patients.
Ablytx is a biotechnology company headquartered in San Diego and Del Mar, California. The company pioneers a class of medicines designed to selectively remove disease-driving proteins from cell surfaces.
Get ABIONYX PHARMA's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ABIONYX PHARMA in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access